Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Integra Lifesciences Holdings (IART) Raw Materials (2016 - 2017)

Integra Lifesciences Holdings' Raw Materials history spans 7 years, with the latest figure at $48.4 million for Q3 2017.

On a quarterly basis, Raw Materials changed N/A to $48.4 million in Q3 2017 year-over-year; TTM through Sep 2017 was $48.4 million, a N/A change, with the full-year FY2016 number at $39.2 million, changed N/A from a year prior.
Raw Materials hit $48.4 million in Q3 2017 for Integra Lifesciences Holdings, up from $39.2 million in the prior quarter.
Over the last five years, Raw Materials for IART hit a ceiling of $48.4 million in Q3 2017 and a floor of $36.5 million in Q4 2014.
Historically, Raw Materials has averaged $41.1 million across 4 years, with a median of $39.7 million in 2015.